



**SOLVE  
ON.**

## Data from Incyte's Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019

February 28, 2019

WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 28, 2019-- Incyte Corporation (Nasdaq:INCY) announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019. The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.

Accepted abstracts feature data from clinical studies involving Incyte's anti-PD-1 monoclonal antibody, INCMGA0012<sup>1</sup>, in patients with advanced solid tumors, as well as pre-clinical characterizations of the Company's oral, small molecule PD-L1 inhibitor program and its PD-L1xCD137 bispecific antibody.

"Data accepted for presentation during the upcoming AACR Annual Meeting demonstrate our ongoing commitment to advancing innovative research as we seek to bring forward novel therapies for patients with cancer," stated Dashyant Dhanak, Ph.D., Chief Scientific Officer, Incyte. "In particular, we are pleased to present, for the first time at a major medical meeting, early data on our oral PD-L1 inhibitor program—whose lead candidate, INCB86550, recently entered clinical trials."

Key abstracts include:

### **Clinical**

***Pharmacodynamic correlates in a phase 1 study of INCMGA0012, a PD-1 antagonistic monoclonal antibody*** (Abstract #CT085/9, Phase 1 Clinical Trials: Part 3)

- Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 16

***Assessment of flat dosing strategy for INCMGA0012 in patients with advanced tumors***(Abstract #LB-268/14, Late-Breaking Research: Experimental and Molecular Therapeutics)

- Wednesday, April 3, 2019, 8:00 a.m. – 12:00 p.m. ET, Poster Section 40

### **Pre-Clinical**

#### **Oral Presentations**

***Novel small-molecule antagonists of the PD-1/PD-L1 axis that mediate cell surface PD-L1 dimerization and internalization*** (Abstract #4483, Novel Therapeutics)

- Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m. ET, Georgia Ballroom 3 – Georgia World Congress Center (Building C)

***Preclinical characterization of potent and selective oral PD-L1 small-molecule antagonists*** (Abstract #4480, Novel Therapeutics)

- Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m. ET, Georgia Ballroom 3 – Georgia World Congress Center (Building C)

#### **Poster Presentations**

***A bispecific Fc-silenced IgG1 antibody (MCLA-145<sup>2</sup>) requires PD-L1 binding to activate CD137*** (Abstract #539/3, Therapeutic Antibodies I)

- Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 23

***An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties*** (Abstract #541/5, Therapeutic Antibodies I)

- Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 23

***Characterization of human cancer cell line xenografts in humanized mice*** (Abstract #1050/1, Human in Mouse)

- Monday, April 1, 2019, 8:00 a.m. – 12:00 p.m. ET, Poster Section 4

Full session details and data presentation listings for AACR 2019 can be found at: <https://www.abstractsonline.com/pp8/#!/6812>.

### **About Incyte**

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at [www.incyte.com](http://www.incyte.com).

Follow @Incyte on Twitter at <https://twitter.com/Incyte>.

### **Forward-Looking Statements**

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's development pipeline and its presentation plans for the upcoming AACR annual meeting, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company's development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ending December 31, 2018. Incyte disclaims any intent or obligation to update these forward-looking statements.

<sup>1</sup> INCMGA0012 licensed from MacroGenics, Inc.

<sup>2</sup> MCLA-145 development in collaboration with Merus, NV.



View source version on businesswire.com: <https://www.businesswire.com/news/home/20190228005257/en/>

Source: Incyte Corporation

### **Media**

Catalina Loveman

+1 302 498 6171

[cloveman@incyte.com](mailto:cloveman@incyte.com)

### **Investors**

Michael Booth, DPhil

+1 302 498 5914

[mbooth@incyte.com](mailto:mbooth@incyte.com)